Company Focus
Lundbeck
Latest Lundbeck News
Latest Lundbeck News
Pharmaceutical
Danish CNS specialist Lundbeck today released first-quarter 2025 financials, along with a raised guidance for the full year, sending its shares up more than 9% to 28.80 kroner. 14 May 2025
Pharmaceutical
The European Commission (EC) has approved Danish CNS specialist Lundbeck and Otsuka Pharmaceutical Europe’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. 13 March 2025
Pharmaceutical
Danish CNS specialist Lundbeck today released financial results for fourth-quarter and full-year 2024. 5 February 2025
Biotechnology
Danish CNS specialist Lundbeck announced positive results from the 12-month open-label extension of the Phase Ib/IIa PACIFIC trial, evaluating bexicaserin in participants aged 12-65 with developmental and epileptic encephalopathies (DEEs). 30 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Latest CNS News & Features
Latest CNS News
Insights
Company Spotlight
A biotech company developing vectorized antibody approaches for the treatment of neurodegenerative diseases.
Latest News & Features of interest to Lundbeck
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Pharmaceutical
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 10 June 2025
Biotechnology
Dutch late-stage biotech NewAmsterdam Pharma late yesterday announced positive top-line data from prespecified Alzheimer’s disease (AD) biomarker analyses in the Phase III BROADWAY clinical trial (NCT05142722). The firm’s US-traded shares were up 4.1% at $20.99 in pre-market activity this morning. 10 June 2025
Biotechnology
AI-enabled biotech Juvenescence today announced the acquisition of Ro5 Inc, a proprietary AI drug discovery company. 9 June 2025
Biotechnology
The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the development of new drug therapy options to treat this disease, according to a report from DelveInsight. 6 June 2025
Biotechnology
US commercial-stage drugmaker Corcept Therapeutics has presented results from its DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS) at the European Network to Cure ALS (ENCALS) 2025 annual meeting. 6 June 2025
Biotechnology
US clinical-stage biotech Vigil Neuroscience today announced a disappointing update on the Phase II IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). 4 June 2025
Pharmaceutical
Neuropsychiatric disorders specialist Alto Neuroscience, has entered into an asset purchase agreement with Chase Therapeutics Corporation to buy a portfolio of potentially best-in-class dopamine agonist drug combinations. 4 June 2025
Pharmaceutical
Japanese biotech Nxera Pharma has received a $15 million payment from Neurocrine Biosciences after the first patient was dosed in a Phase III study of NBI-1117568, a potential new treatment for schizophrenia. 3 June 2025
Biotechnology
Netherlands-based biotech VectorY Therapeutics, which is developing treatments for neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). 2 June 2025
Latest In Brief for Lundbeck
Biotechnology
US cell and gene therapy specialist Mustang Bio has announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts, and concurrent divestment of certain fixed assets including furniture and equipment to an AbbVie unit for $1.0 million. 3 March 2025
Latest CNS Ones To Watch News
CNS Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze